CSF2 and hereditary clear cell renal cell carcinoma: Another trial, NCT00458536, is investigating a dendritic cell–renal cell carcinoma fusion vaccine plus granulocyte macrophage colony stimulating factor (GM-CSF) for the treatment of RCC.